Home » Drug Information » FDA-Approved Drugs » 1998
Medical Areas: Endocrinology | Musculoskeletal | Obstetrics/Gynecology
View By: Year Company Therapeutic Areas Drug Names
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Solvay Pharmaceuticals
Approval Status: Approved March 1998
Treatment Area: prevention of osteoporosis
Estratab (.3 mg ) has been approved for the prevention of
osteoporosis.
In a two-year clinical trial, women on .3 mg Estratab tablets
showed increased bone mineral density over baseline in the spine,
hip, and whole body.
Women taking this low dose also experienced fewer side effects,
such as headache, nausea, breast tenderness, and vaginal bleeding,
than women on higher doses.
